Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWX9 | ISIN: US87583X1090 | Ticker-Symbol:
NASDAQ
23.04.25
21:59 Uhr
1,465 US-Dollar
0,000
0,00 %
1-Jahres-Chart
TANGO THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
TANGO THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur TANGO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.04.Tango Therapeutics cuts nearly one-fifth of staff2
25.03.Tango Therapeutics, Inc.: Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 20252
27.02.Tango Therapeutics, Inc.: Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights118- TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer - - Investigational New Drug (IND) application for TNG456, a next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor...
► Artikel lesen
27.02.Tango Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
TANGO THERAPEUTICS Aktie jetzt für 0€ handeln
27.02.Tango Therapeutics, Inc. - 10-K, Annual Report-
27.02.Tango Therapeutics, Inc. - 8-K, Current Report1
13.01.Tango Therapeutics, Inc. - 8-K, Current Report2
05.12.24Unveiling 5 Analyst Insights On Tango Therapeutics6
06.11.24Tango Therapeutics GAAP EPS of -$0.27 beats by $0.07, revenue of $11.6M beats by $3.53M3
06.11.24Tango Therapeutics treibt Krebsmedikament in die Vollentwicklung8
06.11.24Tango Therapeutics advances cancer drug into full development3
06.11.24Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights225BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines...
► Artikel lesen
06.11.24Tango Therapeutics, Inc. - 10-Q, Quarterly Report-
06.11.24Tango Therapeutics, Inc. - 8-K, Current Report-
07.08.24Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights204BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines...
► Artikel lesen
23.05.24Medivir's licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program265STOCKHOLM, May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need...
► Artikel lesen
08.05.24Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights164BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1